X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DIVIS LABORATORIES ELDER PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -0.2 30.0 - View Chart
P/BV x 0.1 5.2 1.9% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ELDER PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DIVIS LABORATORIES
Mar-17
ELDER PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3801,222 31.1%   
Low Rs188784 24.0%   
Sales per share (Unadj.) Rs491.2153.1 320.8%  
Earnings per share (Unadj.) Rs-3.239.9 -8.0%  
Cash flow per share (Unadj.) Rs14.444.6 32.3%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs376.5201.8 186.6%  
Shares outstanding (eoy) m20.54265.47 7.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.66.6 8.8%   
Avg P/E ratio x-89.325.1 -355.5%  
P/CF ratio (eoy) x19.722.5 87.6%  
Price / Book Value ratio x0.85.0 15.2%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m5,833266,266 2.2%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m2,1794,687 46.5%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m10,08940,643 24.8%  
Other income Rs m257749 34.3%   
Total revenues Rs m10,34641,392 25.0%   
Gross profit Rs m-79214,460 -5.5%  
Depreciation Rs m3611,233 29.3%   
Interest Rs m2,75623 12,196.0%   
Profit before tax Rs m-3,65313,953 -26.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1253,349 3.7%   
Profit after tax Rs m-6510,604 -0.6%  
Gross profit margin %-7.835.6 -22.1%  
Effective tax rate %-3.424.0 -14.3%   
Net profit margin %-0.626.1 -2.5%  
BALANCE SHEET DATA
Current assets Rs m9,24040,105 23.0%   
Current liabilities Rs m9,9986,595 151.6%   
Net working cap to sales %-7.582.5 -9.1%  
Current ratio x0.96.1 15.2%  
Inventory Days Days46119 39.1%  
Debtors Days Days6081 74.3%  
Net fixed assets Rs m10,12419,995 50.6%   
Share capital Rs m206531 38.7%   
"Free" reserves Rs m5,58253,043 10.5%   
Net worth Rs m7,73453,574 14.4%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88261,585 37.2%  
Interest coverage x-0.3618.4 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.7 66.8%   
Return on assets %11.817.3 68.2%  
Return on equity %-0.819.8 -4.3%  
Return on capital %22.326.1 85.5%  
Exports to sales %3.00-   
Imports to sales %0.425.2 1.7%   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m4310,259 0.4%   
Fx inflow Rs m30735,384 0.9%   
Fx outflow Rs m12510,399 1.2%   
Net fx Rs m18124,985 0.7%   
CASH FLOW
From Operations Rs m11,75411,493 102.3%  
From Investments Rs m-561-11,372 4.9%  
From Financial Activity Rs m-6,762-93 7,262.9%  
Net Cashflow Rs m4,43228 15,604.6%  

Share Holding

Indian Promoters % 39.6 52.0 76.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 16.8 19.0 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.2 209.9%  
Shareholders   16,479 31,796 51.8%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS